Crystal arthritis: New ACR guidelines for gout management hold some surprises

Nature Reviews Rheumatology

Volumn 9, Issue 1, 2013, Pages 9-11

  Bardin, Thomas ^a   Richette, Pascal ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; COLCHICINE; FEBUXOSTAT; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PREDNISOLONE; PREDNISONE; STEROID; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR; ANTIGOUT AGENT; ANTIINFLAMMATORY AGENT;

DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; ETHNICITY; GOUT; HUMAN; HYPERURICEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; SHORT SURVEY; SYSTEMIC THERAPY; TOPHACEOUS GOUT; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; URIC ACID BLOOD LEVEL; ACUTE DISEASE; ARTICLE; BLOOD; MEDICAL SOCIETY; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOLOGY; UNITED STATES;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, GOUTY; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATOLOGY; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84871774550     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.216     Document Type: Short Survey

References (9)

1. Doherty, M. et al. Gout: why is this curable disease so seldom cured? Ann. Rheum. Dis. 71, 1765-1770 (2012).
2. Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 63, 3136-3141 (2011).
3. Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken) 64, 1431-1446 (2012).
4. Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. (Hoboken) 64, 1447-1461 (2012).
5. Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312-1324 (2006). (Pubitemid 44620440)
6. Jordan, K. M. et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46, 1372-1374 (2007).
7. Hung, S. I. et al. HLA-B*5801 as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad. Sci. USA 102, 4134-4139 (2005).
8. Somkrua, R., Eickmann, E. E., Soakaew, S., Lohitnavy, M. & Chaiyakunapruk, N. Association of HLA-B*5801 allele and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrosis: a systematic review and meta-analysis. BMC Med. Genet. 12, 118 (2011).
9. Terkeltaub, R. A. et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 62, 1060-1068 (2010).